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Abstract
Background—Although lifestyle and medications are effective for coronary heart disease 
(CHD) risk reduction, few studies have examined the comparative effectiveness of various 
strategies for delivering high quality CHD risk reduction. In this paper, we report on the design 
and baseline characteristics of participants for just such a trial.
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Methods—We conducted a randomized trial of the same lifestyle and medication intervention 
delivered in two alternate formats: counselor-delivered or web-based. The trial was conducted at 5 
diverse practices in a family medicine research network and included men and women age 35–79 
who were at high risk of CHD events based on 10-year predicted Framingham risk of ≥10% or a 
known history of cardiovascular disease. After individual-level randomization, participants in both 
arms received a decision aid plus four intensive intervention visits and 3 maintenance visits over 
12 months. The primary outcome was change in 10-year predicted CHD risk among patients 
without prior cardiovascular disease. Secondary outcomes, measured among all participants, 
included changes in CHD risk factors, cost-effectiveness, and acceptability at 4 and 12-month 
follow-up.
Results—We randomized 489 eligible patients: 389 without and 100 with a known history of 
cardiovascular disease. Mean age was 62.3. 75% were white, 25% African American. 45% had a 
college education. 88% had health insurance. Mean 10-year predicted CHD risk was 16.9%.
Conclusion—We have successfully recruited a diverse sample of practices and patients that will 
provide a rich sample in which to test the comparative effectiveness of two strategies to implement 
high quality CHD prevention.
Keywords
Coronary Heart Disease; Prevention; Counseling; Therapy/Computer-Assisted; Evidence-Based 
Practice
1. Introduction
Coronary heart disease (CHD) is responsible for one-third of deaths in the United States and 
is one of the leading causes of premature, permanent disability [1]. This high medical and 
financial burden has made CHD a critical public health issue for the United States and 
prompted national campaigns to improve prevention of CHD [2] by reducing the 
development of CHD risk factors (primordial prevention) and by treating elevated risk 
factors in those without and with known CHD (primary and secondary prevention, 
respectively).
Fortunately, lifestyle changes and medication are effective for CHD risk reduction. High 
quality observational data has shown that a healthful lifestyle (including not smoking, 
maintaining a healthy weight, getting regular physical activity, eating a healthy diet, and 
consuming alcohol only in moderation) are associated with rates of CHD that are 80% lower 
than people who do not demonstrate these behaviors [3]. Additionally, a recent randomized 
trial suggests a 30% reduction in major cardiovascular events with a diet high in fruits, 
vegetables, and fish, supplemented with nuts, or olive oil [4]. Furthermore, multiple high 
quality randomized trials and meta-analyses have demonstrated statins, hypertension 
medicines, and aspirin each reduce the risk of CHD events (myocardial infarction (MI) and 
CHD death) by 25–30% [5–12].
Given clear evidence of the benefits of lifestyle changes and medication for CHD risk 
reduction, what is at issue is not what needs to be done to reduce CHD risk, but how to do it 
effectively and efficiently. Investigators and practitioners have tried a host of interventions 
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to reduce CHD risk. These fall broadly into 3 categories: pharmacist or educator led 
programs for lifestyle and medication counseling [13–15]; interactive health technology 
(e.g. computerized education, decision aids, and counseling; and automated telephone calls) 
[16, 17]; and referrals to community counseling programs (e.g. nutrition counseling, 
smoking quit lines) [18, 19]. All have shown some success in primary care settings, but few 
have jointly addressed both lifestyle changes and medications [14, 20, 21]. Additionally, few 
have been comparatively tested to determine their relative effectiveness, cost effectiveness, 
and acceptability.
In this paper, we present the protocols and participant characteristics for a study comparing 
the effectiveness of the same lifestyle and medication intervention for CHD prevention 
delivered in two alternate formats: counselor-delivered or web-based. Given recent national 
interest in both comparative effectiveness research [22, 23] and strategies to improve the 
delivery of clinical care [24], we believe a detailed description of the study design, and 
ultimately the results, should be of interest to a wide range of stakeholders (researchers, 
practicing health professionals, patients, and payers).
2. Methods
2.1. Study overview
To assess the comparative effectiveness of two alternate formats of CHD prevention 
(counselor-delivered vs. web-based), we conducted a randomized trial at 5 diverse family 
medicine practices located in central North Carolina (see Figure 1). Our primary intent was 
to determine the interventions’ effect in patients without prior cardiovascular disease (CVD; 
previous MI, coronary artery bypass surgery, coronary angioplasty or stent placement, 
transient ischemic attack or stroke or known peripheral vascular disease or angina). We 
secondarily tested our intervention in a smaller sample of patients with known CVD to 
generate hypotheses about whether counseling and web-interventions work similarly or 
differently in secondary prevention patients. Study outcomes included effectiveness, cost-
effectiveness, and acceptability assessed at 4- and 12-month follow-up. The University of 
North Carolina at Chapel Hill’s Biomedical Institutional Review Board (IRB) approved and 
monitored this study. The trial was registered at clinical trials.gov (NCT01245686).
2.2. Stakeholder engagement
To inform development and future dissemination of our intervention, we convened a single 
focus group of health care decision makers in North Carolina. Participants were purposively 
sampled to represent key-stakeholders in CHD prevention and included 5 men and 2 women 
representing the North Carolina (NC) Health Quality Alliance, the NC Division of Public 
Health, the NC Foundations for Advanced Health Program, the American Heart Association, 
Community Care of NC, and the Veterans Administration (VA). The focus group was 
conducted by the Director for Formative Research at UNC’s Center for Health Promotion 
and Disease Prevention and content followed a structured discussion guide. The session was 
digitally recorded, transcribed, and checked for accuracy. Then a key point analysis was 
performed. Decision makers emphasized the importance of low cost, effective interventions 
that are practical, acceptable to end-users, and implementable with the resources available in 
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practice. They also emphasized the need to target multiple (rather than single) risk factors; 
target both primary and secondary prevention; and teach lifestyle and medication 
management skills applicable to a range of disease prevention and treatment strategies. We 
incorporated this input throughout our trial development to help us design our counselor-
delivered and web-based interventions, collect data that would be of interest to major 
stakeholders, and increase the likelihood of future dissemination.
2.3. Setting
We conducted our study in practices affiliated with the North Carolina Family Medicine 
Research Network (NC-FM-RN). The NC-FM-RN is a practice-based research network that 
aims to improve primary care through research and dissemination of evidence-based 
practices. It includes over 63 practices that are representative of North Carolina’s geographic 
and ethnic diversity [25]. Practices include 29 private practices, 22 academic practices, and 
12 community health centers with over 500 practicing clinicians serving 801,000 patients.
We designed our recruitment strategy to ensure a mix of practice types and participants. 
Sampling initially proceeded through a process of optimized random sampling [26]to ensure 
a sample representative of the network. However, too few practices met specified sampling 
criteria to proceed with this approach, thus, we purposively sampled practices according to 
the following criteria: at least 2 practices with a patient population with >20% African-
Americans; and at least 2 practices affiliated with a community health center. Ultimately, we 
recruited two community health centers, two private practices, and one private practice with 
an academic affiliation to participate in our study. Characteristics of included practices are 
shown in Table 1.
2.4. Participant screening
We recruited patients from each of the 5 participating practices to take part in our study. 
Recruitment occurred through a combination of daily chart reviews, self-referrals, and 
clinician referrals. Within each practice, health educators conducted daily chart reviews of 
patients scheduled for routine office visits and advertised for participants with waiting room 
flyers. Clinicians also referred patients felt to be appropriate candidates for the study. 
Inclusion criteria were assessed via chart review and included: established patients at 
participating practices (seen for an office visit within the past 2 years), age 35–79, and at 
high risk for CHD (angina, MI, or CHD death) defined by a Framingham risk score of ≥ 
10% [27] or known CVD. For potentially eligible patients, clinicians completed a clinician 
enrollment form. On this form, clinicians indicated whether patients should be excluded 
based on treatment of psychosis; history of alcohol or substance abuse in the last 2 years; 
pregnancy, breastfeeding, or intention to get pregnant during the ensuing 18 months; 
primary language not English; history of malignancy, other than non-melanoma skin cancer, 
that had not been in remission or cured surgically for >5 years; estimated creatinine 
clearance < 30 ml/min; or recent history of serious hypoglycemia (requiring medical 
attention in the past year). Clinicians also indicated whether or not they approved patient 
participation in the study and specifically participation in the physical activity portion of the 
study.
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With clinician approval, patients were seen by study staff for a formal screening and 
enrollment visit. During the visit, study staff obtained written informed consent, confirmed 
whether or not participants had a prior history of CVD, screened participants for potential 
bleeding risk associated with aspirin, and collected additional data by standard methods 
across practices to assess CHD risk (e.g. blood pressure, blood specimen for lipids) and rule 
out significant renal dysfunction. If participants had known CVD or remained at sufficiently 
high risk of predicted CHD events (≥10%) based on data collected at the enrollment visit, 
they continued participation in the study and were contacted by telephone to assess 
additional baseline measures. They then returned for their first intervention visit.
2.6. Randomization
At the first intervention visit and prior to initiation of the intervention, we randomized 
participants to either the counselor-delivered or web-based interventions. Randomization 
was computer-generated, used 1:1 allocation, and was stratified by study site (5 sites) and 
CHD risk (3 groups: no CVD with CHD risk of 10–19%, no CVD with CHD risk ≥ 20%, 
known CVD). It was also blocked (with block size of 2) to ensure balance between study 
arms among participants enrolled at each site and within CHD risk stratum. Random 
assignment was concealed in an online participant tracking system and revealed to study 
staff only after they indicated that participants had completed baseline study measures.
2.7. Intervention
Our intervention included a combined lifestyle and medication adherence intervention 
delivered in two alternate formats: counselor-delivered or web-based. Participants in both 
arms received a computerized decision aid and then either 7 sessions of counseling from a 
counselor or 7 sessions of interactive tailored messaging on the web (up to 5.5 hours of 
interventional contact; see Figure 2). In designing the intervention, our goal was to deliver 
the same content in both formats. Thus, we designed the scripted counseling and written 
materials in the counselor arm to match the text of the web-based intervention and used the 
same sequencing of materials for both interventions. Given limited resources, the 
intervention was developed only in English. Details about our intervention are provided 
below; further detail is provided in Appendix A.
2.7.1. The evidence for our interventions—The evidence for the diet and physical 
activity components of our interventions was drawn from the literature used in creation of 
the New Leaf intervention [28–31] and updated with 1) the best available evidence on the 
relative risk reductions associated with eating a healthy diet (20–40%) and being physically 
active (10–20%) and 2) recent evidence supporting a focus on dietary fat quality (i.e. eating 
polyunsaturated fats rather than reducing total fat content)[32–38] . The evidence for the 
medication and smoking cessation intervention components was drawn from the evidence-
based Heart to Heart intervention [39] and updated to include new information on aspirin 
and statin side effects from nationally representative cohort data [40, 41]. A stroke risk 
calculator was also added, but only for women who indicated an interest in exploring aspirin 
as an option to reduce their risk, given that recent meta-analyses showed, on average, no 
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benefit of aspirin for CHD risk reduction in women, but clear benefit for stroke risk 
reduction in women [42, 43].
2.7.2. Decision aid—We developed two versions of the decision aid: one for participants 
without CVD but at high risk for CHD events and one for participants with known CVD. 
Both decision aids were modeled after the Heart to Heart decision aid that we previously 
developed and tested [39, 44].
For participants with no history of CVD but who were at high risk of CHD events, the 
decision aid: 1) calculated participants’ 10-year CHD risk using a continuous Framingham 
equation [45], 2) educated participants about their CHD risk, their personal risk factors, and 
the pros and cons of possible risk-reducing strategies including changing diet, increasing 
physical activity, stopping smoking, starting aspirin, and starting or increasing blood 
pressure medicine or cholesterol medicine, 3) showed participants how much their CHD risk 
might be reduced by any single or combination of lifestyle and medication risk reducing 
strategies, and 4) encouraged participants to select the strategies(s) they wish to pursue to 
reduce their risk after encouragement to consider their personal values. Although offering 
patients choices among risk reducing strategies might seem controversial, this approach 
helps patients to match the intensity of their CHD prevention efforts with their concerns for 
safety, cost, and the time commitment for treatments [46]. Further, in prior studies, it has 
been associated with increased adherence and reduced CHD risk [39].
For those with known CVD, the decision aid: 1) described the increased risk for future CHD 
events (20% based on meta-analyses) [47, 48], 2) educated patients about the pros and cons 
of available risk reducing strategies including changing diet, increasing physical activity, 
stopping smoking, taking aspirin, and taking or increasing blood pressure medicine or 
cholesterol medicine, and 3) recommended pursuing all available risk-reducing strategies.
2.7.3. Counselor-delivered and web-based intervention sessions—In either 
format, interventions included 4 intensive sessions (each up to 60 minutes in duration 
depending on participants’ individual pace in the web or counselor-delivered sessions) at 
monthly intervals, followed by 3 maintenance sessions (each 15–30 minutes in duration) 
delivered at 2 month intervals. The first intensive visit was always conducted in the 
participating clinic. Subsequent visits could occur remotely (by phone for those in the 
counselor arm or at home via the web for those in the web-arm) if the participant preferred. 
All counseling was conducted by trained health counselors, who held degrees in nursing, 
social work, or nutrition.
The first intensive session opened with self-assessment of lifestyle and barriers to each 
chosen risk-reducing strategy and continued with content specific education on diet, 
physical activity, smoking cessation, or medication adherence (see Appendix A). For those 
who chose to work on diet, it also included tips to circumvent self-identified barriers to risk 
reduction (see Appendix A) and creation of first steps toward self-identified actionable 
goals. First steps specified exactly what participants would do, when they would get started, 
and what additional resources they needed to start. All subsequent sessions included the 
same basic content regardless of chosen risk reducing strategy: they opened with a check-in 
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on progress toward goals, continued with education and tips to circumvent barriers, and 
finished with identification of new first steps (see Figure 2). All participants received 
ancillary resources including a Heart to Health cookbook, pedometers and physical activity 
logs for self-monitoring of exercise, and an illustrated community resource guide that 
specified local resources for healthy eating (e.g. farmers markets) and physical activity (e.g. 
walking trails).
The content of maintenance sessions was tailored according to participants’ success in 
adhering to their chosen risk reducing strategy(s), which was assessed at the beginning of 
the first maintenance visit. Messages focused on the following basic topics: relapse 
prevention, problem solving, and lessons for long-term maintenance. In the relapse 
prevention session, participants learned to identify and handle “risky” situations in which 
individuals are likely to slip into old behaviors. They also got tips on what to do if they 
slipped (e.g. keep a positive attitude, regroup, seek support from others). In the problem 
solving session, participants learned to define the problem, brainstorm solutions, choose the 
best possible solutions, and plan for implementation of their solutions. Finally, in the session 
on lessons for long-term maintenance, participants were encouraged to renew their 
commitment to heart disease prevention; apply relapse prevention, problem solving, and first 
step planning; monitor their success (using log books, pedometers, blood pressure and 
cholesterol checks, or risk recalculation); and build a support system for success.
2.7.4. Pre-testing the intervention—To ensure that our interventions were 
understandable and usable, we performed cognitive and usability testing on each component 
of the intervention. Testing was conducted until all content and functionality had been 
reviewed by at least two individuals and the research team felt confident that the 
intervention was understood and usable. This required testing in 9 individuals; all met 
inclusion criteria for our trial. To alleviate respondent burden, each participant gave input on 
only a subset of intervention components. However, we assured that each component was 
reviewed by at least two individuals. Iterative revisions of intervention content were 
performed based on this pre-testing.
2.8. Outcomes
We measured 3 types of outcomes in this study: effectiveness, acceptability, and cost-
effectiveness. Effectiveness outcomes were divided into 3 categories. Our primary 
effectiveness outcome was change in 10-year predicted CHD risk in participants without 
known CVD. Secondary outcomes were measured in participants both without and with 
known CVD and included changes in blood pressure, cholesterol, aspirin use, medication 
adherence, dietary behaviors, and physical activity. Tertiary outcomes were measured in all 
participants and included weight, body mass index (BMI), general quality of life and 
outcomes related to possible harms (liver function tests (LFTs), and creatinine (Cr)). All 
outcomes were measured at both 4 months (primary timeframe) and 12 months in both study 
arms. The details of measurements are described below; an overview is provided in Table 2.
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10-year predicted CHD risk (primary outcome): We measured 10-year predicted global 
CHD risk at baseline, 4-month, and 12-month follow-up, using a well-validated 
Framingham risk equation [45]. As we’ve done in our prior work [39], we assumed that the 
benefits of lifestyle and medication are reasonably captured by entering revised risk factor 
data into the Framingham equation. Because aspirin use was not accounted for by the 
Framingham equation, we modeled the effects of aspirin on CHD risk using a 23% risk 
reduction for men and a 0% reduction for women [49]. Patients with diabetes were not 
considered to have a risk equivalent to those with known CVD, thus we calculated CHD risk 
for patients with diabetes.
CHD risk factors (secondary outcomes): We measured CHD risk factors at baseline, 4 
month, and 12-month follow-up, through a combination of measures applied using well-
defined protocols. We measured blood pressure using a non-invasive oscillometric 
automatic monitor (Omron HEM-907) after the patient has been seated for at least 5 
minutes. We averaged three measurements taken at one minute intervals, and defined 
hypertension as a systolic measurement >140 mm Hg. We measured serum total and HDL 
cholesterol using enzymatic testing and direct LDL cholesterol using enzymatic/
spectrophotometric testing without sample pre-treatment (LabCorp, Burlington, NC). We 
measured aspirin use by self-report (yes/no) with confirmation of reported aspirin use by 
serum thromboxane level (Laboratory for Clinical Biochemistry Research, University of 
Vermont); serum thromboxane levels of <500 pg/ml were considered indicative of aspirin 
use based on prior experience of the laboratory and the results of pilot testing in 10 patients 
(5 with and 5 without known aspirin use). We measured smoking status by self-report (>100 
cigarettes: yes/no) with confirmation by urine dipstick using the NicAlert test strips (Jant 
Pharmacal; Encino, CA) in those who reported quitting. A test strip measure of 3 or higher 
(cotinine concentration >100 ng/ML) was considered an indication of tobacco use. We 
assessed fruit and vegetable intake and fat quality using a combination of brief validated 
questionnaires and biomarkers. We measured fruit and vegetable intake using a 10-item food 
frequency screener that is highly correlated with fruit and vegetable intake on more intensive 
food frequency questionnaires (spearman rho 0.7) [50]; we also assessed serum carotenoids 
(Molecular Epidemiology and Biomarker Research Laboratory, University of Minnesota, 
Minneapolis, MN), which are correlated with servings of fruit and vegetable intake per day 
(i.e. a 27% relative increase corresponds to a 5 serving/day increase in reported intake). We 
assessed fat quality using a slightly modified version of a recently validated 20-item 
questionnaire measuring intake of unsaturated, saturated, and trans fats[51]. On a subsample 
of participants (N = 298), we also assessed red blood cell membrane fatty acids as a 
biomarker of fatty acid intake (Molecular Epidemiology and Biomarker Research 
Laboratory, University of Minnesota, Minneapolis, MN). We measured physical activity 
using a modified version the RESIDE questionnaire, which provides a reliable estimate of 
the amount of moderate and intense physical activity per week [52, 53]. We then assessed 
steps per day using a pedometer that stores the previous 41 days of steps and aerobic steps 
(Omron HJ-720ITC, A Helping Hand HeathMed, Benicia, CA).
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Medication adherence (secondary outcome): Self-reported medication adherence was 
measured using the 8-item Morisky score, whose categorical assessment of high adherence 
(8 =high, 6–7=medium adherence, <6= low adherence) has been associated with better 
blood pressure control [54]. We focused on the proportion of individuals with high 
adherence and verified high adherence by correlating it with expected changes in blood 
pressure (−4 mmHg) and cholesterol (−20 mg/dl) based on 50% of the standard change 
reported in meta-analyses of treatment trials. [55, 56]
Tertiary outcomes: To assess other variables of interest, we measured weight using 
electronic scales (Seca 770, Seca Corporation, Columbia, MD), and sent blood to a central 
laboratory for testing of serum creatinine, aspartate aminotransferase (AST), and hgba1c 
(Labcorp, Burlington, NC).
2.9.2. Acceptability of the Interventions—We assessed the acceptability of 
interventions to both participants and providers by asking participants how much they 
agreed that the intervention were useful, understandable, trustworthy, motivating, and 
important in helping them decide about CHD risk reduction. We also asked providers to 
report how much they agree that Heart to Health was helpful in motivating patients, 
understanding patients’ values for risk reducing options, and getting counseling done. All 
answers were provided on a 5-point Likert scales, ranging from strongly agree to strongly 
disagree. Secondary measures of acceptability asked participants and providers to report on 
the helpfulness of various components of the intervention and to comment on the amount of 
information and time spent with the intervention. Providers were also asked to report on the 
usefulness of the intervention outside the research setting.
2.9.3. Cost-effectiveness—We assessed the cost per 1 absolute percentage point 
reduction in CHD risk from the participant, payer, and societal (sum of participant and 
payer) perspectives. Participant costs included participant time (assessed by the average 
hourly wage of US adults) and travel. Payer costs included labor and non-labor costs. Labor 
costs included market value for staff time associated with intervention delivery. Non-labor 
costs included costs for materials related to intervention delivery (business and appointment 
cards, postage, pedometers, cookbooks, binders and laptops for the web arm) and rent at the 
practices hosting the intervention.
2.10. Sample size and power considerations
With available resources, we planned to enroll 600 patients, including 500 with no known 
CVD who would form the primary sample for analysis and 100 with known CVD who 
would be included only in secondary analyses. Sample size and power estimates were 
obtained for mean changes within and mean differences between groups in the primary 
outcome (10-year predicted risk of CHD events at 4 month follow-up in those with no 
known CVD). Based on our prior work, we anticipated a 1.5 percentage point change in 10-
year predicted CHD risk from baseline to 4 months follow-up. Further, we expected that we 
might see as much as a 0.9 percentage point difference between groups in this outcome. 
Using a one-sided test, a standard deviation of 3.1 units, an α=0.05, and an expected 10% 
attrition, we estimated that we needed 225 participants in each arm provide >99% power to 
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detect a within group difference in CHD risk. This sample size would then secondarily allow 
an 85% power to detect a 0.9 percentage point difference in predicted CHD risk between the 
counselor and web arms. The size of our secondary prevention subgroup (i.e. those with 
known CVD) was determined based on the sample size we deemed necessary to test the 
feasibility and acceptability of the intervention in this population.
2.11. Quality control and intervention fidelity
To ensure the quality of our conclusions, all research staff completed rigorous training on 
data collection and intervention delivery protocols. After an initial four-day training, follow-
up trainings occurred at one and five months. We also audio-recorded and reviewed one of 
each of the 7 intervention counseling session (Sessions 1–7) per counselor. Counselors 
received feedback to standardize the content of the counseling session and ensure optimum 
counseling techniques consistent with principle of motivational interviewing.
2.12. Analysis
In this paper, we report descriptive statistics to compare the baseline characteristics of those 
randomized to the counselor and web-arms. For study outcomes, we will ultimately use the 
analysis plan that follows.
For analysis of our primary outcome, change in 10-year predicted CHD risk within 
intervention arms, we will use a one-sided paired t-test at each point in time. Following the 
example of others, we will exclude participants who develop a CVD event during the study 
period from our primary analysis [57–60]. All analyses will be intent-to-treat. Additionally, 
for the primary outcome, we plan to test multiple approaches for imputing missing follow-
up data including last observations carried forward, multiple imputation, and consecutive 
0.5% predicted risk increases to allow determination of any thresholds where conclusions 
might change.
To secondarily compare changes in predicted CHD risk between intervention arms at each 
point in time, we will use a linear regression model including baseline Framingham risk 
score and clinic as fixed effects. Inclusion of baseline scores as covariate is a more powerful 
test than comparing changes across time between two groups [61, 62]. We plan to adjust 
treatment comparison between groups for select baseline variables deemed relevant to 
behavior change a priori (age, race, educational achievement, and BMI) and for additional 
covariates that differ between intervention groups at baseline (p < 0.10). Other secondary 
and tertiary analyses will examine variables of interest using paired t-tests or McNemar chi-
square tests for within group comparisons and mixed effects models for between group 
differences, adjusting for covariates as described above.
To assess cost-effectiveness, we will calculate incremental cost-effectiveness ratios for the 
webarm compared with usual care, and for the counselor arm compared with the web arm. 
SAS version 9.3 will be used for all analyses, with p ≤ .05 considered significant.
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In accordance with our recruitment procedures, we identified 2744 potentially eligible 
patients via chart review and obtained approval from clinicians for 1427 of them to 
participate (see Figure 1). Of these, 755 refused participation (largely due to lack of interest 
or perceived need or lack of transportation) and 39 could not be contacted. Thus, we 
enrolled 633 in the study.
After baseline risk assessment with standard methods across practices, 109 had Framingham 
risk scores of less than 10% and 524 remained eligible for participation. Of these, 490 were 
ultimately randomized within their risk stratum (390 with no known cardiovascular disease 
and 100 with it). These 490 patients were spread across the 5 participating practices (131 
from Practice 1, 104 from Practice 2, 81 from Practice 3, 88 from Practice 4, and 78 from 
Practice 5) and were seen by 29 different clinicians.
Among those without prior cardiovascular disease (n=389), the main focus of our trial, 195 
were randomized to the counselor arm and 195 to the web-arm. We subsequently 
determined that one was ineligible and excluded them from analyses. The remaining sample 
of 389 participants without known cardiovascular disease still provided >99% power to 
detect a 1.5 percentage point change in CHD risk from baseline to 4 month follow-up 
(primary aim) and 80% power to detect a 0.9 percentage point difference in CHD risk 
between groups. Baseline characteristics in this group were evenly distributed (see Table 3) 
with no appreciable differences in age, race, income, education, health insurance, CHD risk, 
CHD risk factors, or self-reported risk reducing behaviors. Slightly more participants in the 
counselor arm were women and slightly more had a prescription drug plan, however, these 
differences were not statistically different.
Among those with prior cardiovascular disease (n=100; designed for hypothesis generation), 
52 were randomized to the counselor arm and 48 to the web arm. Again, there were few 
clinically meaningful baseline differences (see Table 3). However, participants in the 
counselor arm were significantly more likely to live with a spouse or someone like a spouse 
(79% versus 58%).
4. Discussion
In this paper, we described the research protocols we used for studying the comparative 
effectiveness of the same CHD prevention intervention delivered in two alternate formats: 
counsel-delivered or web-based. We also demonstrated the recruitment of a diverse sample 
of practices and participants. We anticipate that both interventions in this study will reduce 
CHD risk. Further, we anticipate that this study will provide critical information that can 
help clinicians, practices, and payers understand the tradeoffs in implementing various types 
of interventions, overall and in different patient populations and settings, and help them 
determine how to best use their limited resources.
The interventions evaluated in this study have several key features that should ensure 
reductions in CHD risk. First, they start with previously tested and successful lifestyle and 
medication interventions. Second, they combine these interventions, making it likely they 
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will achieve greater risk reduction than either intervention alone. Third, each intervention 
starts with a decision aid that calculates CHD risk and models the achievable risk reduction 
possible with various combinations of lifestyle and medications; previous evidence suggests 
this is an effective motivator for risk reduction [44, 63]. Finally, our study staff has been 
rigorously trained to ensure fidelity of intervention delivery.
This study also has key features that will ensure useful information for clinicians, practices, 
and payers making decisions about how to best implement interventions to reduce CHD risk. 
First, it is a rigorously designed randomized comparative effectiveness trial with attention to 
key methodological issues that would reduce selection bias, measurement bias, and 
confounding. Second, it examines a range of outcomes (e.g. effectiveness, acceptability, and 
cost-effectiveness) that are relevant to those making decisions about implementation of care. 
Third, it provides 12-month as well as 4 month follow-up data, allowing clinicians to make 
determinations about the impact of various implementation methods on long term health 
outcomes. Fourth, the diversity of practice types and resources in this study may allow 
inferences about moderators of intervention effect. Finally, the study’s sample and practices, 
which are representative of the primary care delivered in North Carolina, should increase 
generalizability of findings.
With CHD prevention designated as a national priority and practice redesign high on the 
minds of many clinicians, practices, and payers, our study is poised to offer help to decision 
makers making critical decisions about how to best serve the needs of their patients and 
implement and sustain high quality CHD prevention in a cost effective manner. Future work 
will be important to expand our intervention to important subgroups not targeted by the 
current intervention (e.g. Latinos).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Overview of measures
Measure Measurement Detail Lab
Efficacy Measures
10-year Predicted CHD Riska 
(Primary)
• Framingham Risk Equation predicting angina, MI, CHD 
death [44]
Blood pressure • Average of 3 measurements taken at 1 minute intervals 
using oscillometric automatic monitor (Omron 
HEM-907)
Cholesterol (Total, HDL, LDL) • Serum total and HDL cholesterol
• Direct LDL
LabCorp, Burlington NC
Aspirin use • Single item self-report (yes/no)
• Serum thromboxane if reported use (levels <500 confirm 
use)
Laboratory for Clinical 
Biochemistry Research, 
University of Vermont
Smoking status • Single item self-report (>100 cigarettes: yes/no)
• Urinary cotinine if reported quitting (3 or higher 
confirms smoking)
Jant Pharmacal; Encino, CAb
Fruit and vegetable intake • 10-item Block Screener [48]
• Serum carotenoids (27% relative increase corresponds to 
5 servings/day)
Molecular Epidemiology and 
Biomarker Research Laboratory, 
University of Minnesota, 
Minneapolis, MN
Dietary fat quality • 20-item fat screener [49]
• Red blood cell membrane fatty acids in random 
subsample (n=298)
Molecular Epidemiology and 
Biomarker Research Laboratory, 
University of Minnesota, 
Minneapolis, MN
Physical activity • Modified RESIDE questionnaire [50,51]
• Pedometer steps/day using Omron HJ-720ITC
Medication adherence • 8-item Morisky scale [52]
• Change in blood pressure (−4 mmHg) and cholesterol 
(−20 mg/dL) [53,54]
Acceptability Measures
Acceptability of Intervention • 6-item internally developed score assessing overall 
acceptability to patients
• 7-item internally developed score assessing overall 
acceptability to providers
• Secondary measures assessing the helpfulness of the 
intervention, the amount of information and time spent 
with various intervention components, and for providers 
the usefulness of the intervention outside the research 
context
Cost-Effectiveness Measures
Cost-Effectiveness • Incremental cost for 1% reduction in CHD risk from 
provider, payor, and societal perspectives
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a
In those with no known CVD only
b
Tested at the point of care using supplies provided by Jant Pharmacal
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